

New, Independent, Non-Executive Director to be Appointed

✓ **Gavin Fox-Smith to join the Board as a Non-Executive Director.**

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (“**Rhythm**” or the “**Company**”) is pleased to announce the appointment of Mr Gavin Fox-Smith as a new, Independent Non-Executive Director effective 2 December 2024. Mr Fox-Smith is one of Australia’s most experienced and respected leaders in the MedTech industry, with a broad experience encompassing both large multinational and smaller, domestic companies.

About - Gavin Fox-Smith BSc, MBA, GAICD

Gavin has been a leader and champion of Medical Technology across Australia/NZ and Asia. He has also played lead Governance and Executive roles in Industry Bodies, Innovation Initiatives and Not for Profit Boards. Gavin is strong advocate for Gender Equality and Indigenous Engagement.

His career spans over 35 years, previously holding the position of Managing Director Australia/NZ and Vice President Asia Pacific for Johnson & Johnson Medical Devices, Chair of the Medical Technology Association of Australia, Governor of American Chamber of Commerce, Co-Founder/Chair of Macquarie Park Business Coalition (in partnership with United Way) and Australian Co-Chair of the Health Technology Sector Group of the Australia/NZ Leadership Forum.

Gavin is currently transitioning out of his executive CEO role at Omnigon, a private Australian company in the Ostomy Care market. He is at this time, Chair of ANDHealth (Australia’s National Digital Health Initiative), Board Director for Bowel Cancer Australia and Board Director for SAN Foundation. Gavin is a proud member of the Champions of Change Coalition STEM/Health group and serves as Ambassador for Rotary Oceania Medical Aid for Children (ROMAC).

Gavin is a Graduate of the Australian Institute of Company Directors and recently completed the AICD Boardroom Mastery program.

Rhythm Non-Executive Chairman, Otto Buttula, commented:

“On behalf of the Company, we are delighted that Gavin has agreed to join the Board of Rhythm. We believe his extensive skills and broad experience will be instrumental in assisting us reach our commercialisation objectives. Additionally, Gavin’s wide network and connections with key stakeholders in the global MedTech ecosystem will offer valuable insights to guide us during what we anticipate being a period of significant growth.”

Australian Registered Address

Directors

Incoming Independent Non-Executive Director, Mr Gavin Fox-Smith, commented:

“I’m thrilled to join the board of Rhythm Biosciences. My lifelong commitment to enhancing public health drives my passion for improving outcomes for people suffering Bowel Cancer and I believe Rhythm’s recent advancements align perfectly with this mission.

The Company has the potential to revolutionise Bowel Cancer detection on a global scale. I’m eager to collaborate with the team as we move toward commercialisation and unlock the potential of this innovative Australian technology. Additionally, I’m excited to contribute to the development of other simple yet transformative diagnostic products, leveraging my skills and expertise to support Rhythm’s global expansion.

In particular, Rhythm’s initial product ColoSTAT® was a major drive for me, as Bowel Cancer is one of those diseases where, if we catch it early enough, we can actually do something about it. While we may not be able to eradicate bowel cancer, we certainly can improve clinical and social outcomes for patients. I believe that early detection is key to improving outcomes, and I am excited to be part of the effort to make a meaningful impact.”

- ENDS -

Authorised for release by the Board.

For further information contact us via investor@rhythmbio.com:

Dr David Atkins Chief Executive Officer & Managing Director	Ms Andrea Steele Joint Company Secretary & General Counsel
--	---

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.